По вашему запросу найдено документов: 307

Страница 3 из 31

ПРИМЕНЕНИЕ ЭРИТРОПОЭТИНОВ В КОМБИНАЦИИ С ВНУТРИВЕННЫМИ ПРЕПАРАТАМИ ЖЕЛЕЗА ПРИ ХИМИОИНДУЦИРОВАННОЙ АНЕМИИ В ОНКОЛОГИИ
APPLICATION OF ERITROPOETINS IN THE COMBINATION WITH INTRAVENOUS PREPARATIONS OF IRON AT CHEMIOINDUCED ANEMIA IN ONCOLOGY
Л. Н. Кудряшова, L. N. Kudryashova (Креативная хирургия и онкология, №1-2, 2017)
Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial
Alexeeva, E, Horneff, G., Dvoryakovskaya, T., Denisova, R., Nikishina, I., Zholobova, E., Malievskiy, V., Santalova, G., Stadler, E., Balykova, L., Spivakovskiy, Y., Kriulin, I., Alshevskaya, A., Moskalev, A. (2021)
to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Onorato, Eustaquio Maria, Onorato, Eustaquio Maria, Muratori, Manuela, Smolka, Grzegorz, Wojakowski, Wojtek, Pysz, Piotr, Zorinas, Aleksejus, Zakarkaite, Diana, Eltchaninoff, Hélène, Litzer, Pierre-Yves, Godart, François, Calvert, Patrick, Christou, Christos, Mussayev, Abdurashid, Missiroli, Bindo, Buzaev, Igor, Curello, Salvatore, Tesorio, Tullio, Bartorelli, Antonio Luca (2022)
deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium
Gillessen, S, Sauve, N, Collette, L, Daugaard, G, de Wit, R, Albany, C, Tryakin, A, Fizazi, K, Stahl, O, Gietema, JA, De Giorgi, U, Cafferty, F.H., Hansen, A.R., Tandstad, T, Huddart, R.A., Necchi, A, Sweeney, C.J., Garcia-Del-Muro, X, Heng, DYC, Lorch, A, Chovanec, M, Winquist, E, Grimison, P, Feldman, D.R., Terbuch, A, Hentrich, M, Bokemeyer, C, Negaard, H, Fankhauser, C, Shamash, J., Vaughn, DJ, Sternberg, CN, Heidenreich, A, Beyer, J (2021)
, and Australia. Clinical trial and registry data were included. Primary end points were progression-free survival
Обзор механизма действия и результатов клинических исследований противогрибкового препарата ибрексафунгерп
Reviewing the mechanism of action and results of clinical studies on the antifungal drug ibrexafungerp
Tagirova, Leysan I., Farvazova, Kamila R., Valeeva, Daniia R., Orlova, Maria D., Gubaidullin, Irik A., Tulyabaeva, Adelina M., Abdulmanova, Ailina R., Tryapko, Ruslan V., Shelyginsky, Daniil A., Khanafieva, Anzhelika R., Semenova, Nastasia G., Takiullin, Eduard M., Тагирова, Л.И., Фарвазова, К.Р., Валеева, Д.Р., Орлова, М.Д., Губайдуллин, И.А., Тулябаева, А.М., Абдульманова, А.Р., Тряпко, Р.В., Шелыгинский, Д.А., Ханафиева, А.Р., Семенова, Н.Г., Такиуллин, Э.М. (2024)
. Проведен поиск публикаций в электронных базах данных PubMed, еLibrary и ClinicalTrials.gov, опубликованных
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial
Burtness, B., Haddad, R., Dinis, J., Trigo, J., Yokota, T, De Souza Viana, L., Romanov, I., Vermorken, J., Bourhis, J., Tahara, M., Martins Segalla, J.G., Psyrri, A., Vasilevskaya, I., Nangia, C.S., Chaves-Conde, M., Kiyota, N., Homma, A., Holeckova, P., Del Campo, J.M., Asarawala, N., Nicolau, U.R., Rauch, D., Even, C., Wang, B., Gibson, N., Ehrnrooth, E., Harrington, K., Cohen, E.E.W. (2019)
. Design, Setting, and Participants: This multicenter, phase 3, double-blind randomized clinical trial (LUX
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Kristeleit, Rebecca, Lisyanskaya, Alla, Fedenko, Alexander, Dvorkin, Mikhail, de Melo, Andreia Cristina, Shparyk, Yaroslav, Rakhmatullina, Irina, Bondarenko, Igor, Colombo, Nicoletta, Svintsitskiy, Valentyn, Biela, Luciano, Nechaeva, Marina, Lorusso, Domenica, Scambia, Giovanni, Cibula, David, Póka, Róbert, Oaknin, Ana, Safra, Tamar, Mackowiak-Matejczyk, Beata, Ma, Ling, Thomas, Daleen, Lin, Kevin K, McLachlan, Karen, Goble, Sandra, Oza, Amit M (2022)
dose of assigned study treatment. This study is registered with ClinicalTrials.gov, NCT02855944
The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study
Lomakin, NV, Bakirov, BA, Protsenko, DN, Mazurov, VI, Musaev, GH, Moiseeva, OM, Pasechnik, ES, Popov, VV, Smolyarchuk, EA, Gordeev, IG, Gilyarov, MY, Fomina, DS, Seleznev, AI, Linkova, YN, Dokukina, EA, Eremeeva, AV, Pukhtinskaia, PS, Morozova, MA, Zinkina-Orikhan, AV, Lutckii, AA (2021)
trial was to evaluate the efficacy and safety of IL-6 receptor inhibitor levilimab (LVL) in subjects
Применение препарата, содержащего технологически обработанные антитела к каннабиноидному рецептору 1-го типа, для лечения ожирения у взрослых: результаты многоцентрового двойного слепого плацебо-контролируемого рандомизированного клинического исследования
The use of drug based on technologically processed antibodies to endocannabinoid receptor type 1 in the treatment of obesity in adults: results of a multicenter double blind placebo controlled randomized clinical trial
Demidova, TY, Krasil'nikova, EI, Vorob'ev, SV, Morugova, TV, Adasheva, TV, Демидова, Т.Ю., Красильникова, Е.И., Воробьев, С.В., Моругова, Т.В., Адашева, Т.В. (2021)
trial
Treatment of Metastatic Renal Cell Carcinoma with Checkpoint Inhibitors in Clinical Practice in the Volga-Ural Region of the Eurasian Continent
Rakhimov, Radmir R., Sultanbaev, Aleksandr V., Izmailov, Adel A., Menshikov, Konstantin V., Zabelin, Vadim M., Izmailov, Albert A., Izmailov, Albert A., Izmailova, Svetlana M., Bakhtiyarova, Ksenia S., Izmailova, Angelina A., Gilyazova, Irina R. (2023)
neoplasms. Methods: Data from clinical trials have shown good progression-free median and median overall

Страница 3 из 31

Google Scholar
OpenDoar

Фасеты

Научный руководитель
Авторы
Ключевые слова
Год